DrugCite
Search

LOPINAVIR

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Lopinavir Adverse Events Reported to the FDA Over Time

How are Lopinavir adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Lopinavir, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Lopinavir is flagged as the suspect drug causing the adverse event.

Most Common Lopinavir Adverse Events Reported to the FDA

What are the most common Lopinavir adverse events reported to the FDA?

Immune Reconstitution Syndrome
142 (2.29%)
Drug Exposure During Pregnancy
127 (2.05%)
Lipodystrophy Acquired
114 (1.84%)
Drug Interaction
100 (1.61%)
Eyelid Ptosis
80 (1.29%)
Mitochondrial Toxicity
73 (1.18%)
Diplopia
72 (1.16%)
Progressive External Ophthalmoplegi...
69 (1.11%)
Diarrhoea
67 (1.08%)
Portal Hypertension
67 (1.08%)
Premature Baby
65 (1.05%)
Show More Show More
Vomiting
62 (1%)
Atrioventricular Block Complete
59 (.95%)
Pyrexia
57 (.92%)
Pregnancy
56 (.9%)
Anaemia
42 (.68%)
Renal Failure Acute
38 (.61%)
Weight Decreased
36 (.58%)
Abortion Spontaneous
34 (.55%)
Intra-uterine Death
34 (.55%)
Congestive Cardiomyopathy
32 (.52%)
Nausea
31 (.5%)
Maternal Drugs Affecting Foetus
30 (.48%)
Headache
29 (.47%)
Hypotension
29 (.47%)
Osteonecrosis
29 (.47%)
Fatigue
28 (.45%)
Nephropathy Toxic
28 (.45%)
Portal Hypertensive Gastropathy
28 (.45%)
Abdominal Pain
27 (.44%)
Hepatotoxicity
27 (.44%)
Cardiomyopathy
26 (.42%)
Confusional State
26 (.42%)
Death
26 (.42%)
Sepsis
26 (.42%)
Splenomegaly
26 (.42%)
Alanine Aminotransferase Increased
25 (.4%)
Blood Alkaline Phosphatase Increase...
25 (.4%)
Renal Failure
25 (.4%)
Dehydration
24 (.39%)
Lactic Acidosis
24 (.39%)
Thrombocytopenia
24 (.39%)
Ascites
23 (.37%)
Aspartate Aminotransferase Increase...
23 (.37%)
Pancytopenia
23 (.37%)
Asthenia
22 (.36%)
Condition Aggravated
22 (.36%)
Haemoglobin Decreased
22 (.36%)
Hypokalaemia
22 (.36%)
Premature Rupture Of Membranes
22 (.36%)
Drug Toxicity
21 (.34%)
Hepatic Failure
21 (.34%)
Pneumonia
21 (.34%)
Pulmonary Hypertension
21 (.34%)
Abortion Induced
20 (.32%)
Blood Creatinine Increased
20 (.32%)
Blood Triglycerides Increased
20 (.32%)
Drug Resistance
20 (.32%)
Gamma-glutamyltransferase Increased
20 (.32%)
Neutropenia
20 (.32%)
Stillbirth
20 (.32%)
Gastroenteritis
19 (.31%)
Osteoporosis
19 (.31%)
Platelet Count Decreased
19 (.31%)
Varices Oesophageal
19 (.31%)
General Physical Health Deteriorati...
18 (.29%)
Neuropathy Peripheral
18 (.29%)
Decreased Appetite
17 (.27%)
Lymphadenopathy
17 (.27%)
Premature Labour
17 (.27%)
Abdominal Distension
16 (.26%)
Blood Hiv Rna Increased
16 (.26%)
Caesarean Section
16 (.26%)
Cardiac Murmur
16 (.26%)
Dyspnoea
16 (.26%)
Hepatic Steatosis
16 (.26%)
Hepatomegaly
16 (.26%)
Nodular Regenerative Hyperplasia
16 (.26%)
Oesophageal Varices Haemorrhage
16 (.26%)
Treatment Failure
16 (.26%)
Aids Encephalopathy
15 (.24%)
Congenital Anomaly
15 (.24%)
Cough
15 (.24%)
Hepatitis
15 (.24%)
Jaundice
15 (.24%)
Myalgia
15 (.24%)
Pallor
15 (.24%)
Rash
15 (.24%)
Depression
14 (.23%)
Dizziness
14 (.23%)
Hypertension
14 (.23%)
Mobility Decreased
14 (.23%)
Myocardial Infarction
14 (.23%)
Oedema Peripheral
14 (.23%)
Pancreatitis
14 (.23%)
Pneumothorax
14 (.23%)
Pulmonary Tuberculosis
14 (.23%)
Respiratory Failure
14 (.23%)
Tachycardia
14 (.23%)
White Blood Cell Count Decreased
14 (.23%)
Arthralgia
13 (.21%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Lopinavir, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lopinavir is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Lopinavir

What are the most common Lopinavir adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Lopinavir, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lopinavir is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Lopinavir According to Those Reporting Adverse Events

Why are people taking Lopinavir, according to those reporting adverse events to the FDA?

Hiv Infection
1280
Antiretroviral Therapy
94
Drug Use For Unknown Indication
62
Prophylaxis Against Hiv Infection
51
Drug Exposure During Pregnancy
31
Acquired Immunodeficiency Syndrome
26
Show More Show More
Product Used For Unknown Indication
25
Antiviral Prophylaxis
22
Hiv Test Positive
16
Systemic Antiviral Treatment
13
Maternal Exposure Timing Unspecifie...
13
Human Immunodeficiency Virus Transm...
10
Maternal Exposure During Pregnancy
9
Antiviral Treatment
7
Prophylaxis
7
Viral Infection
6
Pregnancy
5
Exposure During Breast Feeding
4
Retroviral Infection
4
Malaria Prophylaxis
3
Hiv Infection Cdc Category A1
3
Cd4 Lymphocytes Decreased
2
Foetal Exposure During Pregnancy
2
Kaposis Sarcoma
2
Renal Transplant
2
Progressive Multifocal Leukoencepha...
1
Mycobacterium Avium Complex Infecti...
1
Ill-defined Disorder
1
Antifungal Prophylaxis
1
Hiv Infection Cdc Category B2
1
Acute Hiv Infection
1
Congenital Hiv Infection
1
Drug Level
1
Hepatitis B
1
Hiv Infection Cdc Category B3
1

Drug Labels

LabelLabelerEffective
KaletraState of Florida DOH Central Pharmacy13-APR-10
KaletraREMEDYREPACK INC. 27-SEP-10
KaletraRebel Distributors Corp28-DEC-10
KaletraPD-Rx Pharmaceuticals, Inc.03-MAR-11
KaletraHHS/Program Support Center/Supply Service Center06-MAR-12
KaletraPhysicians Total Care, Inc.06-APR-12
KaletraDispensing Solutions, Inc.10-OCT-12
KaletraDispensing Solutions, Inc.10-OCT-12
KaletraAbbVie Inc.28-JAN-13
KaletraCardinal Health14-MAR-13

Lopinavir Case Reports

What Lopinavir safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Lopinavir. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Lopinavir.